For most people, HPV is not serious. About 80% to 90% of infections clear on their own within two years, never causing symptoms or health problems. But a small percentage of infections persist, and those can lead to genital warts or, over many years, cancer. The gap between “usually harmless” and “potentially deadly” is what makes HPV confusing, so the real answer depends on which type you have, how long you’ve had it, and whether you’re getting screened.
Most HPV Infections Disappear on Their Own
HPV is incredibly common. Most sexually active people will get at least one type at some point in their lives. The immune system handles the vast majority of these infections quietly, clearing the virus within one to two years without any treatment. These short-lived infections do not cause cancer and typically produce no symptoms at all. You can have HPV, clear it, and never know it was there.
Only about 10% to 20% of infections become persistent, meaning the virus sticks around for years instead of being eliminated. Persistence is the key factor that separates a harmless infection from a dangerous one. A single positive HPV test, on its own, is not a reason to panic. It’s a reason to follow up with your doctor on the recommended timeline and monitor whether the infection resolves.
High-Risk vs. Low-Risk Strains
There are over 200 types of HPV, but they fall into two broad categories that behave very differently.
Low-risk types (mainly types 6 and 11) cause genital warts. Warts are a nuisance, not a danger. They can be treated and removed, though they often recur within the first three months after treatment. In rare cases, these same low-risk types can cause growths on the vocal cords of infants born to mothers with genital warts, a condition called recurrent respiratory papillomatosis. This is uncommon enough that it’s not typically a reason to change birth plans, but it’s something your OB should know about.
High-risk types (especially types 16 and 18) are the ones linked to cancer. These two strains alone cause 70% of cervical cancers worldwide. But even with a high-risk strain, cancer is not inevitable. The progression from persistent infection to precancerous cell changes to invasive cancer typically takes 10 to 20 years. That slow timeline is what makes screening so effective: there’s a wide window to catch and remove abnormal cells before they become malignant.
The Cancers HPV Can Cause
HPV is responsible for roughly 37,800 cancer cases each year in the United States. Cervical cancer gets the most attention, but it’s far from the only HPV-related malignancy.
- Cervical cancer: Virtually all cases are caused by HPV. Globally, cervical cancer is the fourth most common cancer in women, with about 660,000 new cases and 350,000 deaths in 2022. A staggering 94% of those deaths occurred in low- and middle-income countries where screening and vaccination are limited.
- Anal cancer: Over 90% of cases are caused by HPV. This affects both men and women.
- Throat cancer: HPV causes 60% to 70% of oropharyngeal cancers in the U.S. This is actually rising, particularly in men.
- Penile cancer: About 63% of cases are linked to HPV.
- Vulvar and vaginal cancers: Also significantly driven by HPV, though these are less common overall.
HPV Risks for Men
There’s a widespread misconception that HPV is primarily a women’s health issue. Men carry it, transmit it, and get cancer from it. About 10% of men have oral HPV at any given time, compared to 3.6% of women, and oral HPV infection becomes more common with age. Because there’s no approved HPV screening test for men, and no routine way to check for oral or anal HPV, many men don’t know they’re infected until a problem appears.
HPV-related throat cancer is now more common in men than HPV-related cervical cancer is in women in some high-income countries. Symptoms include a persistent sore throat, earaches, hoarseness, swollen lymph nodes, pain when swallowing, and unexplained weight loss. Using tobacco and alcohol together raises the risk further.
How Screening Catches Problems Early
In countries with strong screening programs, cervical cancer has become largely preventable. The current U.S. guidelines recommend different approaches depending on your age. Women aged 21 to 29 should get a Pap test every three years. Women aged 30 to 65 have three options: a Pap test every three years, an HPV test alone every five years, or both tests together every five years. Screening is not recommended before age 21 or after 65 (for women with a history of normal results).
These intervals might seem long, but they reflect the slow pace of HPV-related changes. Precancerous cells don’t appear overnight. If your screening results are normal, a three- or five-year gap is safe. If results are abnormal, your doctor will recommend closer follow-up, which might mean repeat testing in one year or a procedure to examine the cervix more closely.
The lack of equivalent screening for men, and for non-cervical HPV cancers in general, is a genuine gap. There is no standard test to screen for HPV in the throat, anus, or penis. This makes vaccination and awareness especially important.
How Well the Vaccine Works
The current HPV vaccine protects against nine types, including the two responsible for most cancers and the two that cause most genital warts. In clinical trials, the vaccine prevented 97.4% of high-grade precancerous lesions caused by the five additional cancer-linked strains it covers beyond the earlier version. Real-world data continues to show sharp declines in both HPV infections and precancerous changes in vaccinated populations.
The vaccine is recommended for everyone starting at age 11 or 12, though it can be given as early as 9 and is approved for adults up to age 45. It works best before any exposure to HPV, which is why early vaccination matters. But even if you’ve already been exposed to one strain, the vaccine still protects against the others you haven’t encountered.
What Actually Makes HPV Dangerous
The seriousness of HPV comes down to a few specific risk factors. A persistent infection with a high-risk strain is the baseline requirement for cancer to develop. On top of that, smoking significantly increases the risk of cervical and other HPV-related cancers because it weakens the immune response in affected tissues. A suppressed immune system, whether from HIV, organ transplant medications, or other conditions, makes it harder to clear the virus and raises the odds of persistence.
Lack of access to screening is the biggest risk factor globally. The reason 94% of cervical cancer deaths happen in lower-income countries isn’t because the virus is more aggressive there. It’s because women aren’t being screened, so precancerous changes go undetected until they’ve progressed to invasive cancer. In countries with established screening programs, cervical cancer rates have dropped dramatically over the past several decades.
For the average person in a country with good healthcare access, HPV is a manageable risk. Get vaccinated if you’re eligible, follow screening recommendations, and know that the vast majority of infections resolve without intervention. The small fraction that don’t are exactly what screening is designed to catch.